Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
A phase 3 trial of Tislelizumab, Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by BeiGene, active and no longer recruiting.
Overview
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma is a phase 3 interventional study registered as NCT03967977 by BeiGene, with 420 participants enrolled, started 2019-05-29 and due to reach its primary completion in 2027-06-30. Interventions recorded: Tislelizumab, Placebo, Cisplatin, Gemcitabine Hydrochloride and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Shares Tislelizumab, BeOne Medicines (formerly BeiGene) and the tag pipeline.